Press release from the PRESERVE 2 phase 3 trial

Paolo Tarantino shared a post on X:

“Press release from the PRESERVE 2 phase 3 trial: the addition of trilaciclib to 1L chemo for mTNBC did not improve Overall Survival in the Intention To Treat (n=187) with an Hormone Receptor of 0.91 (p=0.884). The median Overall Survival in the trilaciclib/chemo arm was 17.4 mo vs 17.8 mo in the control arm.”

Further Reading.
Source: Paolo Tarantino/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.